Susquehanna International Group, LLP Crispr Therapeutics Ag Call Options Transaction History

Susquehanna International Group, LLP

$527 Billion
Q2 2024

Call Options

27 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$51.17 - $68.18 $19.4 Million - $25.9 Million	-379,200 Reduced 51.86%	352,000 $19 Million
Q1 2024 May 07, 2024	SELL	$60.67 - $89.12 $11.1 Million - $16.3 Million	-182,400 Reduced 19.96%	731,200 $49.8 Million
Q4 2023 Feb 14, 2024	BUY	$38.62 - $72.18 $20.4 Million - $38.2 Million	528,700 Added 137.36%	913,600 $57.2 Million
Q3 2023 Nov 14, 2023	SELL	$45.39 - $59.0 $1.52 Million - $1.98 Million	-33,500 Reduced 8.01%	384,900 $17.5 Million
Q2 2023 Aug 11, 2023	BUY	$43.47 - $67.77 $7.96 Million - $12.4 Million	183,200 Added 77.89%	418,400 $23.5 Million
Q1 2023 May 16, 2023	SELL	$41.0 - $56.12 $8.15 Million - $11.2 Million	-198,700 Reduced 45.79%	235,200 $10.6 Million
Q4 2022 Feb 14, 2023	SELL	$39.19 - $65.67 $7.2 Million - $12.1 Million	-183,800 Reduced 29.76%	433,900 $17.6 Million
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $4.48 Million - $6.14 Million	73,300 Added 13.46%	617,700 $40.4 Million
Q2 2022 Aug 15, 2022	BUY	$43.23 - $73.83 $8.48 Million - $14.5 Million	196,200 Added 56.35%	544,400 $33.1 Million
Q1 2022 May 16, 2022	BUY	$53.19 - $79.24 $6.14 Million - $9.14 Million	115,400 Added 49.57%	348,200 $21.9 Million
Q4 2021 Feb 14, 2022	BUY	$70.09 - $111.29 $1.93 Million - $3.06 Million	27,500 Added 13.4%	232,800 $17.6 Million
Q3 2021 Nov 15, 2021	SELL	$110.2 - $156.64 $20.9 Million - $29.7 Million	-189,800 Reduced 48.04%	205,300 $23 Million
Q2 2021 Aug 11, 2021	BUY	$100.84 - $161.89 $5.84 Million - $9.37 Million	57,900 Added 17.17%	395,100 $64 Million
Q1 2021 May 17, 2021	BUY	$110.72 - $210.04 $1.64 Million - $3.11 Million	14,800 Added 4.59%	337,200 $41.1 Million
Q4 2020 Feb 16, 2021	BUY	$79.67 - $173.23 $1.42 Million - $3.08 Million	17,800 Added 5.84%	322,400 $49.4 Million
Q3 2020 Nov 16, 2020	SELL	$78.5 - $100.64 $1.03 Million - $1.32 Million	-13,100 Reduced 4.12%	304,600 $25.5 Million
Q2 2020 Aug 14, 2020	BUY	$38.5 - $76.05 $5.61 Million - $11.1 Million	145,700 Added 84.71%	317,700 $23.3 Million
Q1 2020 May 15, 2020	SELL	$33.68 - $62.53 $373,848 - $694,083	-11,100 Reduced 6.06%	172,000 $7.3 Million
Q4 2019 Feb 14, 2020	SELL	$36.68 - $73.13 $579,544 - $1.16 Million	-15,800 Reduced 7.94%	183,100 $11.2 Million
Q3 2019 Nov 14, 2019	BUY	$40.99 - $52.56 $1.03 Million - $1.32 Million	25,200 Added 14.51%	198,900 $8.15 Million
Q2 2019 Aug 14, 2019	BUY	$35.45 - $48.2 $223,335 - $303,660	6,300 Added 3.76%	173,700 $8.18 Million
Q1 2019 May 15, 2019	BUY	$28.02 - $40.87 $1.6 Million - $2.34 Million	57,200 Added 51.91%	167,400 $5.98 Million
Q4 2018 Feb 14, 2019	SELL	$22.73 - $42.34 $1.72 Million - $3.2 Million	-75,600 Reduced 40.69%	110,200 $3.15 Million
Q3 2018 Nov 14, 2018	SELL	$44.35 - $65.71 $2.39 Million - $3.54 Million	-53,900 Reduced 22.49%	185,800 $8.24 Million
Q2 2018 Aug 14, 2018	BUY	$42.62 - $73.59 $5.92 Million - $10.2 Million	139,000 Added 138.03%	239,700 $14.1 Million
Q1 2018 May 15, 2018	BUY	$23.52 - $58.17 $1.04 Million - $2.58 Million	44,300 Added 78.55%	100,700 $4.6 Million
Q4 2017 Feb 14, 2018	BUY	$16.95 - $23.48 $955,980 - $1.32 Million	56,400	56,400 $1.32 Million

Others Institutions Holding CRSP

# of Institutions

523

Shares Held

58M

Call Options Held

1.73M

Put Options Held

1.84M

Capital International Investors Los Angeles, CA

7.87M
Shares

$358 Million
0.09% of portfolio
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl

7.78M
Shares

$355 Million
3.82% of portfolio
Nikko Asset Management Americas, Inc.

3.15M
Shares

$144 Million
1.99% of portfolio
Sumitomo Mitsui Trust Holdings, Inc.

3.15M
Shares

$144 Million
0.13% of portfolio
Black Rock Inc. New York, NY

2.78M
Shares

$127 Million
0.0% of portfolio

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.56B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account